A1F Therapeutic Development Network (TDN)

Helping Bring New Alpha-1 Treatments Forward—With Patients at the Center  

The Alpha-1 Foundation (A1F) Therapeutic Development Network (TDN) helps to develop a cure for Alpha-1 Antitrypsin Deficiency (Alpha-1) by working closely with Alpha-1 experts and research centers across the U.S. to make it easier for patients and families to learn about studies, participate safely, and have their real-life experiences inform Alpha-1 research.

Why the TDN Matters

Clinical research is essential to advancing care for Alpha-1—but finding and joining studies can feel overwhelming or out of reach.

The TDN was created by the Alpha-1 Foundation to:

• Expand access to Alpha-1 research, no matter where you live
• Reduce the burden of participation through virtual and remote options
• Ensure studies — including those evaluating treatments after approval — reflect what matters most to people living with Alpha-1
• Protect patient trust through strong A1F oversight

What Participation Looks Like

Depending on the study, participating in the TDN may include:

• Learning about Alpha-1 studies you may be eligible for
• Connecting with experienced Alpha-1 research centers
• Participating from home through virtual visits when possible
• Contributing to long-term research that improves understanding of Alpha-1, including studies that monitor treatments after they are approved
• Participation is always voluntary, and your medical care stays between you and your healthcare provider.

Your Privacy and Trust Come First

The TDN is owned and governed by the Alpha-1 Foundation.

All research activities follow strict privacy and ethical standards.

Your information is handled securely and respectfully, and you choose whether or not to take part.

Ready to Get Involved?

If you or a family member has Alpha-1, enrolling in the TDN is an important step toward helping advance research and future treatment options.

Enrollment requires participation in the Alpha-1 Research Registry.